Centene

Centene Reports Q4 Results Above Estimates, Guides FY26 Adj. EPS Above Estimates

Centene shares fall 10.61% after-hours as GAAP loss and $6.7B goodwill impairment weigh on results.

Centene Corporation Share Price Plunges 6% Amidst Management's Challenging Day

康西哥

Centene's 15-Min Chart: Bollinger Bands Narrowing, KDJ Death Cross Signal

Centene Forecasts 40% EPS Growth in 2026, Eyes Margin Recovery and Medicaid Stability.

Catalyst<ul> <li>Small and Medium-sized fund flows show positive inflow trends suggesting potential short-term support for CNC.</li></ul>Risk<ul> <li>Technical indicators show that the market is in a volatile state and the direction is not clear enough.</li> <li>Bearish signals are obviously dominant with three bearish indicators reported in the recent technical analysis.</li> <li>Large and Extra-large fund flows indicate negative outflows which could increase downward pressure on CNC.</li></ul>

Key Factors

Centene reported Q4 2025 results with a GAAP diluted loss per share of $(13.53) and adjusted diluted earnings per share of $2.08, while guiding for 2026 adjusted diluted EPS exceeding $3.00. CNC shares fell 10.61% in after-hours trading due to a $513 million non-cash impairment charge and a GAAP loss driven by elevated health benefits ratios and the pending Magellan Health divestiture. Centene’s Q4 revenue rose to $49.73 billion, up from $40.81 billion in the same quarter last year, despite a $1.10 billion net loss and a $1.19 adjusted loss per share. The company forecasts 40% EPS growth in 2026 amid efforts to stabilize Medicaid margins and recover from 2025 challenges including rising medical costs and declining Medicaid enrollment.

CNC News